47 results
Page 2 of 3
8-K
EX-99.1
5yoqbs
4 Jun 21
POINT Biopharma Announces First Patients
4:22pm
425
EX-99.1
cl0l6bo9y9k1z
4 Jun 21
Business combination disclosure
4:20pm
8-K
EX-99.1
c3kd7k9w3fklx
1 Jun 21
POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility
4:32pm
425
EX-99.1
d2vlr4oxur189djm91
1 Jun 21
Business combination disclosure
4:30pm
S-4/A
nzlqaif6rz0scls
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
8-K
EX-99.1
anbwda8faoaacfdwm6
28 Apr 21
POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility
5:13pm
425
EX-99.1
oxu9m
28 Apr 21
Business combination disclosure
5:11pm
S-4
33jpfmir vekv51654su
22 Mar 21
Registration of securities issued in business combination transactions
9:52pm
8-K/A
EX-2.1
kizi pv80qhaen4ag9h4
18 Mar 21
Financial Statements and Exhibits
9:08am
8-K
EX-99.1
zbg8jp8d
15 Mar 21
Public Investor Presentation Transcript
5:20pm
425
EX-99.1
ia4pidywkbb nxmp6
15 Mar 21
Business combination disclosure
8:20am
8-K
EX-99.1
4tiszmc14nbyksxly
15 Mar 21
Next-generation Radiopharmaceuticals Company POINT Biopharma to list on NASDAQ through merger with Research Alliance Corp. I
8:19am
10-K
vr3 vwrue
5 Mar 21
Annual report
8:13am
10-Q
m1zu6zy6f
20 Aug 20
Quarterly report
4:15pm
8-K
EX-99.1
403eprfjyd yj
16 Jul 20
Report of Independent Registered Public Accounting Firm
4:30pm
8-K
EX-99.1
y0oi0us1
10 Jul 20
Therapeutics Acquisition Corp., Sponsored by RA Capital Management, L.P., Announces Pricing of Upsized $118 Million Initial Public Offering
5:17pm